For a few tense weeks, the US legal system flipped the script on mifepristone access. Courts revoked it. Then reinstated it. Back and forth. The abortion pill remains available for home use, via telehealth. For now.
Doctors see the storm clouds. Uncertainty lingers. Policy experts warn that any future rollback won’t just annoy people seeking to end a pregnancies. It will strain the healthcare system. And hurt patients.
Since 2022. Since Dobbs v. Jackson obliterated Roe v. Wade, anti-abortion forces have fixated on this drug. They call mifepristone unsafe. The data disagrees. Overwhelmingly.
First approved in 2000. It works with misoprostol. Up to ten weeks into pregnancy. Tejasvi Gowda is an ob-gyn in Maryland. Also a fellow at Physicians for Reprodutive Health.
“It is incredibly safe. It is one of the most well-studiied drugs in reproductive health care.”
Currently, just over a quarter of all US abortions use mifepristone prescribed virtually. If telehealth dies, choices get hard. In-person care becomes a hurdle. A logistical nightmare for some. An inconvenience for most.
Others? They switch. To misoprostol alone. A pre-2000 regimen. It’s safe. It works. But it carries higher risks than the combo.
REMS restrictions were political, not about safety.
Before the pandemic, the FDA insisted on in-person visits for mifepristone. Tied to the Risk Evaluation and Mitigation Strategy program. REMS usually applies to dangerous meds. Not this one. Amy Friedrich-Karnik at the Guttmacher Institute knows better. She calls the old rules political. Never about science.
The pandemic broke the routine. The FDA lifted the requirement. Made it permanent in 2023.Ushma Upadhyat, a public health scientist at UCSF, watched the change happen. Then studied it.
She tracked more than 6,0 patients. The results are stark. 98% needed zero extra care. Only 15 people (0.25%) faced serious complications like transfusions or hospital stays. Zero deaths. Telehealth works.
But strip that away? Some can’t make it to an office. Travel is impossible. Thirteen states ban abortion almost entirely. Four others stop at six weeks. Telehealth is often the only safe route.
Without the pill? Misoprostol takes over. Rachel Jensen, an ob-gym fellow at ACOG, sees the issue.
Side effects happen with misoprostol anyway. Without mifepristone? You need a higher dose. Jensen calls it not “standard of care.” Gowda agrees. Modern medicine moves forward. This would be a step back.
Providers face new burdens, Upadhyat warns. They’ll update protocols. Spend more time teaching patients. More patients will end up in urgent care or the ER. Just to check if the bleeding is “normal.”
The fear is real. Upadhyat sees providers acting ultraconservative. Even though nothing has been enforced yet. The headlines do the damage.
Experts know this isn’t the end. The Supreme Court will weigh in. Sooner or later. Mary Ziegler is a law professor at UC Davis. She studies abortion policy history. She says the court is inevitable.
The FDA reviews safety too. Experts dread junk science driving those decisions. Declaring the pill unsafe. Based on nothing.
Ob-gym respond to barriers. They adapt.
“We’re used to facing those barriers. And we are ready to do what we have to do. To take care of our patients.” Jensen says this without flinch.
Gowda adds one line. People always find a way. For abortion care. And doctors. We are always there to help.
It doesn’t end with a bang. It drags. Through the courts. Into the waiting room. The next ruling is already circling.
